Advanced Search


Study ID Status Title Patient Level Data
115719 Completed A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 Study Listed on
115720 Completed A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects
115730 Completed PGx423 Pharmacogenetic evaluation of efficacy of lapatinib in EGF104900, EGF20009, EGF105084 and VEG20007
115739 Completed Safety and reactogenicity of GSK Biologicals’ dTpa vaccine (Boostrix™) in healthy Vietnamese children
115774 Completed An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774) Study Listed on
115775 Completed A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers Study Listed on
115777 Completed Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy
115802 Terminated A single-centre, masked, placebo-controlled four part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of the CC-chemokine receptor 3 (CCR3) antagonist, GW824575, coadministered with or without food in healthy male subjects Study Listed on
115805 Completed A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily via the HandiHaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease Study Listed on
115806 Completed A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
115811 Terminated A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
115812 Completed An open label Phase IIIb study to evaluate efficacy and safety of Ambrisentan in Chinese patients with pulmonary arterial hypertension (PAH)
115813 Completed Identification and characterization of bacteria in the lower airways of children aged ≥ 6 months to < 6 years with suspected lower respiratory tract infections (LRTI) in Spain.
115816 Completed A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of L-DOPA in subjects with Parkinson’s disease exhibiting delayed gastric emptying
115829 Relinquished An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with the AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Multiple Myeloma
115830 Completed A Double blind, Placebo controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin induced Inflammatory Response in Healthy Male Subjects Study Listed on
115831 Completed Effects of Brain Derived Neurotrophic Factor (BDNF) gene Polymorphism on Brain Imaging and Behavioural Biomarkers of Plasticity
115860 Completed An open-label, randomized, single centre, 4-way crossover study to evaluate the pharmacokinetics of single oral doses of ezogabine/retigabine in healthy adult Taiwanese subjects Study Listed on
115879 Completed A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection Study Listed on
115884 Completed Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection
115885 Completed WEUSKOP5410: A Retrospective Observational Non-Interventional Nested Case Control Study to Evaluate the Risk for Thromboembolic Events Associated with Surgery and Eltrombopag Exposure in the ENABLE Studies
115887 Completed Safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy female children 4-6 years old
115892 Relinquished An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects with Solid Tumors
115893 Completed A two cohort, open-label study to evaluate the pharmacokinetics of GSK2847065, the metabolite of Retosiban (GSK221149) after single and repeat oral doses, the pharmacokinetics of GSK221149 coadministered with a high fat meal, and the pharmacokinetics of GSK221149 coadministered with an inhibitor of CYP3A4 (Ketoconazole) Study Listed on
115902 Completed A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin from Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects with Acne Vulgaris Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.